New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

Rate this content's potential impact on patient outcomes Submit Rating Thank you! Please share some more information on the ...

Sodium-glucose cotransporter 2 (SGLT2) inhibitors may protect the kidneys better than glucagon-like peptide 1 receptor ...

Use of sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs to treat type 2 diabetes may also help to lower the risk of ...

The use of SGLT2 inhibitors was associated with a significantly reduced risk for dementia and PD in patients with type 2 diabetes.

SGLT2 inhibitors and GLP-1 receptor agonists exhibit renoprotective effects in patients with CKD with and without diabetes.

GLP-1 receptor agonists and SGLT2 inhibitors were both initially approved for type 2 diabetes. But over the last several ...

Off-label SGLT2 inhibitors increase the risk of euglycemic diabetic ketoacidosis. GLP-1RAs may lead to rapid weight loss in ...

A collaboration of researchers led by Emory University Rollins School of Public Health, Atlanta, is urging caution when ...

"In the emulated clinical trial, the use of SGLT2 inhibitors compared to DPP4 inhibits was linked to significantly lower ...

A recent case report highlights the importance of understanding the possibility of the development of Euglycemic diabetic ...

Opens in a new tab or window GLP-1 receptor agonist or SGLT2 inhibitor prescribing became more common for people with type 1 diabetes in recent years, a nationwide cross-sectional analysis found.